In part, this might be because of the increased maturity of NK cells in PD-1-deficient mice, but the reduced frequency of tumor infiltrating NK cells could also be because of (1) reduced CD62L found on the PD-1−/− NK cells or (2) reduced survival once these NK cells encounter tumor cells. The gene discussed is SELL; the disease is neoplasm.